Recent blog posts
Adrenomed presents novel results for their precision medicine therapy with enibarcimab for septic shock
Latest Hotspot
3 min read
Adrenomed presents novel results for their precision medicine therapy with enibarcimab for septic shock
13 September 2023
Adrenomed AG has disclosed recent discoveries regarding the biomarker-directed therapy of septic shock with enibarcimab.
Read →
Clinical trials starts for DS-3939, aimed at treating a variety of complex Advanced Solid Cancers
Latest Hotspot
4 min read
Clinical trials starts for DS-3939, aimed at treating a variety of complex Advanced Solid Cancers
12 September 2023
Daiichi Sankyo has declared that the first patient has been dosed in a first-in-human Phase 1/2 examination evaluating DS-3939.
Read →
VBI Vaccines starts administering their first doses to patients in the Phase 2b trial of VBI-1901
Latest Hotspot
3 min read
VBI Vaccines starts administering their first doses to patients in the Phase 2b trial of VBI-1901
12 September 2023
VBI Vaccines Inc., a biopharma company specializing in immunology, announced that its cancer immunotherapy vaccine candidate, VBI-1901, has begun a Phase 2b trial in patients with first recurrence glioblastoma.
Read →
4DMT reports its first patient for the 4D-150 Phase 2 SPECTRA Clinical Examination in DME
Latest Hotspot
4 min read
4DMT reports its first patient for the 4D-150 Phase 2 SPECTRA Clinical Examination in DME
12 September 2023
4D Molecular Therapeutics has begun the Dose Confirmation stage of their Phase 2 SPECTRA trial, enrolling their first patient. The trial evaluates intravitreal 4D-150 for treating diabetic macular edema.
Read →
Positive Interim results of phase IIa trial for FG001 in head and neck cancer, presented as a case reports at the World Molecular Imaging Congress
Latest Hotspot
3 min read
Positive Interim results of phase IIa trial for FG001 in head and neck cancer, presented as a case reports at the World Molecular Imaging Congress
12 September 2023
FluoGuide A/S is delighted with the preliminary findings from the FG001 study concerning cancer surgery guidance in head & neck cancer patients.
Read →
Tango Therapeutics receives FDA approval for TNG348, a new USP1 inhibitor targeting BRCA1/2-mutant and other HRD+ cancers
Latest Hotspot
3 min read
Tango Therapeutics receives FDA approval for TNG348, a new USP1 inhibitor targeting BRCA1/2-mutant and other HRD+ cancers
11 September 2023
Tango Therapeutics has received FDA clearance for its IND application for TNG348, a new USP1 inhibitor.
Read →
Cidara Therapeutics has announced that Janssen has elected to move forward under their license agreement for novel drug-Fc conjugates targeting influenza
Latest Hotspot
3 min read
Cidara Therapeutics has announced that Janssen has elected to move forward under their license agreement for novel drug-Fc conjugates targeting influenza
11 September 2023
Biotech company Cidara Therapeutics is developing drug-Fc conjugate immunotherapies for serious diseases. Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has given Cidara a go-ahead for CD388 (JNJ-0953), a universal prevention solution for influenza A and B.
Read →
Gloria Biosciences announced that zimberelimab for the treatment of recurrent or metastatic cervical cancer has been successfully listed in China
Latest Hotspot
5 min read
Gloria Biosciences announced that zimberelimab for the treatment of recurrent or metastatic cervical cancer has been successfully listed in China
11 September 2023
Guangzhou Gloria Biosciences has announced that Zimberelimab injection (YuTuo®, GLS-010), has received marketing approval from the China NMPA.
Read →
SpliSense has successfully concluded the Phase 1 clinical trial of SPL84, an RNA-based therapy aimed at treating Cystic Fibrosis
Latest Hotspot
4 min read
SpliSense has successfully concluded the Phase 1 clinical trial of SPL84, an RNA-based therapy aimed at treating Cystic Fibrosis
11 September 2023
SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.
Read →
Verismo Therapeutics provides SynKIR-110 treatment for the first advanced cancer patient in clinical trials
Latest Hotspot
3 min read
Verismo Therapeutics provides SynKIR-110 treatment for the first advanced cancer patient in clinical trials
11 September 2023
Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.
Read →
Viking Therapeutics has launched the Phase 2 VENTURE study of the combined GLP-1/GIP receptor agonist VK2735 for obese patients
Latest Hotspot
4 min read
Viking Therapeutics has launched the Phase 2 VENTURE study of the combined GLP-1/GIP receptor agonist VK2735 for obese patients
11 September 2023
Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.
Read →
FDA authorizes initiation of IND for ATA-100, a Genetic Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Latest Hotspot
3 min read
FDA authorizes initiation of IND for ATA-100, a Genetic Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
11 September 2023
Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.
Read →